You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Attention Score in Context
| Title |
Camrelizumab combined with anlotinib as second-line therapy for metastatic or recurrent small cell lung cancer: a retrospective cohort study
|
|---|---|
| Published in |
Frontiers in oncology, July 2024
|
| DOI | 10.3389/fonc.2024.1391828 |
| Pubmed ID | |
| Authors |
Shujing Shen, Xingya Li, Sanxing Guo, Liang Xu, Ningning Yan |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 July 2024.
All research outputs
#23,710,245
of 26,393,142 outputs
Outputs from Frontiers in oncology
#16,903
of 23,083 outputs
Outputs of similar age
#165,966
of 210,613 outputs
Outputs of similar age from Frontiers in oncology
#144
of 186 outputs
Altmetric has tracked 26,393,142 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 23,083 research outputs from this source. They receive a mean Attention Score of 3.2. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 210,613 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 186 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.